These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 34787884)

  • 21. Chemotherapy-induced cardiotoxicity in children.
    Bansal N; Amdani S; Lipshultz ER; Lipshultz SE
    Expert Opin Drug Metab Toxicol; 2017 Aug; 13(8):817-832. PubMed ID: 28679288
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prevention and management of cardiotoxicity from antineoplastic therapy.
    Chanan-Khan A; Srinivasan S; Czuczman MS
    J Support Oncol; 2004; 2(3):251-6; discussion 259-61, 264-6. PubMed ID: 15328825
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Anticancer therapy induced cardiotoxicity: review of the literature.
    Geiger S; Lange V; Suhl P; Heinemann V; Stemmler HJ
    Anticancer Drugs; 2010 Jul; 21(6):578-90. PubMed ID: 20375725
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cardiotoxicity of cancer chemotherapy: implications for children.
    Simbre VC; Duffy SA; Dadlani GH; Miller TL; Lipshultz SE
    Paediatr Drugs; 2005; 7(3):187-202. PubMed ID: 15977964
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cardiotoxicity associated with cancer therapy: pathophysiology and prevention strategies.
    Adão R; de Keulenaer G; Leite-Moreira A; Brás-Silva C
    Rev Port Cardiol; 2013 May; 32(5):395-409. PubMed ID: 23623503
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Meta-analysis Evaluating the Use of Statins to attenuate Cardiotoxicity in Cancer Patients receiving Anthracyclines and Trastuzumab-based Chemotherapy.
    Shahid I; Yamani N; Ali A; Kumar P; Figueredo V; Unzek S; Mookadam F
    Am J Cardiol; 2021 Oct; 156():142-145. PubMed ID: 34362551
    [No Abstract]   [Full Text] [Related]  

  • 27. Protective Effects of ω-3 PUFA in Anthracycline-Induced Cardiotoxicity: A Critical Review.
    Serini S; Ottes Vasconcelos R; Nascimento Gomes R; Calviello G
    Int J Mol Sci; 2017 Dec; 18(12):. PubMed ID: 29231904
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Chemotherapy-induced cardiotoxicity: new insights into mechanisms, monitoring, and prevention.
    Cadeddu Dessalvi C; Deidda M; Mele D; Bassareo PP; Esposito R; Santoro C; Lembo M; Galderisi M; Mercuro G
    J Cardiovasc Med (Hagerstown); 2018 Jul; 19(7):315-323. PubMed ID: 29708912
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cardiac testing to manage cardiovascular risk in cancer patients.
    Davis M; Witteles RM
    Semin Oncol; 2013 Apr; 40(2):147-55. PubMed ID: 23540740
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cardiac and cardiovascular toxicity of nonanthracycline anticancer drugs.
    Jones RL; Ewer MS
    Expert Rev Anticancer Ther; 2006 Sep; 6(9):1249-69. PubMed ID: 17020459
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Optimizing cardio-oncology programs for cancer patients.
    Francis SA; Asnani A; Neilan T; Scherrer-Crosbie M
    Future Oncol; 2015; 11(14):2011-5. PubMed ID: 26198828
    [No Abstract]   [Full Text] [Related]  

  • 32. Cardiac Outcomes With Pregnancy After Cardiotoxic Therapy for Childhood Cancer.
    Thompson KA; Hildebrandt MA; Ater JL
    J Am Coll Cardiol; 2017 Feb; 69(5):594-595. PubMed ID: 28153113
    [No Abstract]   [Full Text] [Related]  

  • 33. Cardioprotective Strategies to Prevent Cancer Treatment-Related Cardiovascular Toxicity: a Review.
    Upshaw JN
    Curr Oncol Rep; 2020 Jun; 22(7):72. PubMed ID: 32564220
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Autophagy and cancer therapy cardiotoxicity: From molecular mechanisms to therapeutic opportunities.
    Li M; Russo M; Pirozzi F; Tocchetti CG; Ghigo A
    Biochim Biophys Acta Mol Cell Res; 2020 Mar; 1867(3):118493. PubMed ID: 31233802
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Beyond Anthracyclines: Preemptive Management of Cardiovascular Toxicity in the Era of Targeted Agents for Hematologic Malignancies.
    Sethi TK; Basdag B; Bhatia N; Moslehi J; Reddy NM
    Curr Hematol Malig Rep; 2017 Jun; 12(3):257-267. PubMed ID: 28233150
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cardiac Toxicity from Breast Cancer Treatment: Can We Avoid This?
    Caron J; Nohria A
    Curr Oncol Rep; 2018 Jun; 20(8):61. PubMed ID: 29876677
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Scintigraphic techniques for early detection of cancer treatment-induced cardiotoxicity.
    de Geus-Oei LF; Mavinkurve-Groothuis AM; Bellersen L; Gotthardt M; Oyen WJ; Kapusta L; van Laarhoven HW
    J Nucl Med; 2011 Apr; 52(4):560-71. PubMed ID: 21421717
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Fluoropyrimidine-Induced Cardiotoxicity: Manifestations, Mechanisms, and Management.
    Layoun ME; Wickramasinghe CD; Peralta MV; Yang EH
    Curr Oncol Rep; 2016 Jun; 18(6):35. PubMed ID: 27113369
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cardio-oncology: cardiovascular complications of cancer therapy.
    Henning RJ; Harbison RD
    Future Cardiol; 2017 Jul; 13(4):379-396. PubMed ID: 28660778
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dexrazoxane: a cardioprotectant for pediatric cancer patients receiving anthracyclines.
    Wu V
    J Pediatr Oncol Nurs; 2015; 32(3):178-84. PubMed ID: 25366577
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.